Allogene Therapeutics, Inc. Common Stock (ALLO)
Allogene Therapeutics, Inc. is a biotechnology company focused on developing allogeneic CAR T cell therapies for cancer treatment. The company's approach utilizes donor-derived T cells to create off-the-shelf immunotherapies aimed at providing scalable and accessible options for patients with various hematologic malignancies and solid tumors. Founded in 2017, Allogene leverages gene editing technology to enhance the safety and efficacy of its therapies.
Company News
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
Allogene Therapeutics presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma, showing promising results with a 31% confirmed response rate and durable responses in heavily pretreated patients.
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
A more selective small-cap index has consistently outperformed the Russell 2000
Wall Street price targets suggest this stock can rocket more than 400% higher.